SENS News and Press, Senseonics Holdings Inc. From 07/26/22

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2022 fina...

H.C. Wainwright lowered its price target on Senseonics ( NYSE: SENS ) to $3 from $6 in a research note issued on Monday. Stock of a manufacturer and developer of continuous glucose monitoring systems has lost 17% in the past 3 months and 58% in the past on...

3 Industries That Penny Stocks Investors Are Watching If you’re looking for industries to find penny stocks to buy, there are a few that penny stock investors are watching right now. While there are dozens of industries for investors to choose from, it all comes down to knowing y...

Senseonics (NYSE:SENS) said it received CE Mark approval in EU for its next-generation implantable continuous glucose monitoring system (CGM) Eversense E3 CGM. Germantown, Md.-based Senseonics added that its commercial partner Ascensia Diabetes Care will make the system, which can be used for...

The long-term implantable E3 CGM system now approved for commercialization in select European markets Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monito...

The following slide deck was published by Senseonics Holdings, Inc. in conjunction with this event. For further details see: Senseonics (SENS) Investor Presentation - Slideshow

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Undervalued penny stocks have an allure for investors for the simple reason that a little bit goes a long way. Specifically, a small investment that produces a little gain can be very rewarding for investors. But the potent...

Abbott (NYSE:ABT) announced on Tuesday that the U.S. Food and Drug Administration (FDA) cleared its FreeStyle Libre 3 glucose monitoring system (CGM) for diabetic patients aged four years and older. Welcoming the decision, Jared Watkin, senior vice president of Abbott's (ABT) diabetes care, s...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healt...

Senseonics received FDA approval earlier this year for its 180-day continuous glucose monitoring system. Management expects sales to pick up in the second half of this year, along with the rollout of products in the U.S. and Europe. Despite product developments and plenty of opera...